Barely Significant
← all excerpts

Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy.

NPJ Precis Oncol · 2023 · PMC10495439 · PMID 37696887

Europe PMCDOI
1
hedged sentence
0.2000
closest p · 4.0× alpha
0.2000
boldest claim

The sentences

showed a trendP = 0.2not close (p > 0.1)
In stark contrast, the PL group showed a trend toward shorter OS (HR 1.35, 95% CI 0.81–2.25, P = 0.2, Log-rank test) and PFS (HR 1.23, 95% CI 0.79–1.92, P = 0.4, Log-rank test) (Fig. 2a ) in PD-L1 ≥ 1% versus PD-L1 < 1% tumors.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.